Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude First To Market Leadless Pacemaker With Nanostim Buy

This article was originally published in The Gray Sheet

Executive Summary

St. Jude paid $123.5 million and agreed to up to $65 million in additional milestone payments to acquire Nanostim and its first-in-class leadless pacemaker, which has just earned a CE mark and is expected to launch in select European markets soon.

You may also be interested in...



Medtronic Receives CE Mark For World’s Smallest Pacemaker

Medtronic’s Micra Transcatheter Pacing System is not only the world’s tiniest approved pacemaker, but the vitamin-sized transcatheter device also has no leads and is cosmetically invisible. The pacemaker targets patients with a slow heartbeat who can benefit from single-chamber pacing.

Medtronic Enters Leadless Pacemaker Competition With Micra CE Mark

The firm’s ultra-small leadless pacing system has been cleared to launch in Europe, where it will face off with St. Jude’s Nanostim, which is slowly recovering from a pause in implants in 2014.

Device/Diagnostics Quarterly Deal Statistics, Q4 2013

Device companies finished 2013 strong, raising $1.2 billion in Q4, the highest quarter total of the year. CVS Caremark’s $2.1 billion buy of Apria’s infusion therapy business was the largest M&A of the year, and late-stage venture rounds dominated the $423 million total in diagnostics funding.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel